Nationwide, the landscape of the legalized marijuana industry has changed significantly in recent years—no place more so than New England. In 2016, Maine and Massachusetts voted to fully legalize cannabis, and Connecticut, New Hampshire, Rhode Island, and Vermont all allow its use for medical purposes. This panel will examine how the industry’s laws and regulations have evolved in the region, focusing on the experiences of operators who have navigated the sometimes tempestuous legal waters to guide their businesses to success and charted paths to raising capital and investments.
Follow the Money: Analyzing Capital Flow into the Legal Cannabis Industry
This panel will focus on the capital infusions necessary to launch, operate, or invest in the cannabis space, with Viridian providing deal-data insight regarding capital raises and M&A activity. Additional topics will include valuations and structures, as well as the involvement (or lack thereof) of certain investor types (e.g., traditional VCs, institutional investors, etc.) and strategic acquirers (e.g., big alcohol, big tobacco, etc.).
Sector Focus: Cannabinoid-Based Biopharmaceuticals and Personalized Medicine
Cannabinoid-based pharmaceuticals and biotechnologies represent a sub-sector of the industry that could hold the greatest potential value over time. This panel will delve deeply into the research, development, and commercialization of cannabis-based pharmaceuticals, as well as the development of the full data chain needed to create effective personalized medicines from the plant.
The Future of Cannabis
Cannabis is already a multi-billion dollar industry, and its growth is projected to potentially increase at an exponential and possibly unprecedented rate over the coming years. This panel will explore what the future could hold for legalized marijuana, addressing such topics as legal and regulatory changes at the state and federal levels; de- or re-scheduling cannabis under the Controlled Substances Act; changes in interstate and international commerce (i.e., importing/exporting); shifts in business models (e.g., the need for wholesalers, more centralized processing, an additional focus on biotech/pharma, improvements in quality control, the increased value of big data, etc.); and opportunities for investors and capital providers.
For questions and for more information, please contact:
Rashell WilsonBusiness Development CoordinatorBurns & Levinson [email protected]